Is low dose hydroxyurea the solution to the global epidemic of sickle cell disease?
Type
Journal articlePermalink
https://hdl.handle.net/10161/13040Published Version (Please cite this version)
10.1002/pbc.25471Publication Info
(2015). Is low dose hydroxyurea the solution to the global epidemic of sickle cell disease?.
Pediatr Blood Cancer, 62(6). pp. 929-930. 10.1002/pbc.25471. Retrieved from https://hdl.handle.net/10161/13040.This is constructed from limited available data and may be imprecise. To cite this
article, please review & use the official citation provided by the journal.
Collections
More Info
Show full item recordScholars@Duke
John J. Strouse
Associate Professor of Medicine
My research has focused on the epidemiology, risk factors, and prevention of the pulmonary
and central nervous system complications of sickle cell disease and includes retrospective
and prospective cohort studies and clinical trials. I received my Ph.D. in clinical
investigation from the Johns Hopkins Bloomberg School of Public Health for a series
of studies to identify predictors of cognitive function in children with sickle cell
disease. This work has expanded to the evaluation
Articles written by Duke faculty are made available through the campus open access policy. For more information see: Duke Open Access Policy
Rights for Collection: Scholarly Articles
Works are deposited here by their authors, and represent their research and opinions, not that of Duke University. Some materials and descriptions may include offensive content. More info